AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Bank of Stockton

Bank of Stockton grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 48.7% during the third quarter, HoldingsChannel.com reports. The firm owned 4,142 shares of the company’s stock after purchasing an additional 1,356 shares during the period. Bank of Stockton’s holdings in AstraZeneca were worth $323,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. McClarren Financial Advisors Inc. lifted its holdings in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the last quarter. GHP Investment Advisors Inc. bought a new position in AstraZeneca during the second quarter worth $26,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca during the first quarter worth $29,000. Hobbs Group Advisors LLC bought a new position in shares of AstraZeneca in the 2nd quarter worth about $35,000. Finally, Versant Capital Management Inc boosted its holdings in shares of AstraZeneca by 1,614.8% in the 2nd quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock valued at $36,000 after buying an additional 436 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of NASDAQ:AZN traded down $0.33 during trading on Friday, reaching $75.57. The company had a trading volume of 1,041,323 shares, compared to its average volume of 4,998,334. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The firm has a market capitalization of $234.31 billion, a PE ratio of 36.67, a price-to-earnings-growth ratio of 1.43 and a beta of 0.46. The firm’s fifty day moving average is $80.59 and its 200 day moving average is $78.39.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The firm had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the prior year, the firm posted $1.08 earnings per share. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, equities analysts forecast that AstraZeneca PLC will post 4.07 EPS for the current year.

Wall Street Analyst Weigh In

AZN has been the topic of several research reports. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, TD Cowen raised their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.